Spinal cord injury is the most emotionally charged category in stem cell tourism — and the one with the most exaggerated promises. Here's what licensed programs in China actually offer, what the published price bands mean, and why the timing of your injury matters more than any marketing page.
Updated August 2026. China runs the world's most active regulated cell-therapy landscape, and spinal cord injury (SCI) is a major research focus there. But "research focus" is not "commercial cure." The honest picture: licensed programs exist under two frameworks, the evidence is early-stage, and eligibility — especially injury timing — decides everything. We coordinate only the licensed pathway, and we'll tell you plainly if your case isn't a fit.
Licensed stem cell programs in China operate under two frameworks — the same ones we document in detail for stem cell therapy for diabetes:
For SCI specifically, the evidence base is small and early: trials of MSC and other cell products report modest, variable functional gains, and the scientific consensus is that cell therapy at best supports repair alongside rehabilitation — it does not regrow a severed cord. The honest offer from a licensed program is a regulated protocol with realistic, measurable goals for eligible patients, combined with rehabilitation, documented against a written treatment plan.
Short version: no stem cell product for spinal cord injury has NMPA marketing approval as of 2026 — in China or anywhere else. China's first stem cell drug authorization (January 2025, Ruibosheng / umbilical-cord MSC) is for steroid-refractory graft-versus-host disease, not SCI. What exists is a licensed clinical framework: NMPA-regulated trials and NHC-supervised investigator-initiated studies at designated Grade 3A hospitals (141 nationwide as of 2026), plus the Boao Lecheng pilot zone for international patients. Eligibility is decided by the treating team on your imaging and records — not by any clinic's marketing page.
| Eligibility factor | Typical requirement | Why it matters |
|---|---|---|
| Injury timing | Stable injury, typically 3–12+ months post-injury | Acute-phase protocols differ and are mostly trial-based |
| Injury level & completeness | Documented ASIA grade | Determines trial/protocol eligibility |
| Neurological stability | No ongoing active complications | Safety screening |
| Age | 18–65 (varies by protocol) | Trial/protocol inclusion criteria |
| Exclusions | Active infection, severe organ disease, pregnancy | Standard clinical exclusions |
Criteria above are typical published protocol ranges — final eligibility is the treating physician's call on your records. A free eligibility review is the first step.
We have not published a condition-specific price for spinal cord injury, and we won't guess one here. What we can give you is the typical China price band from our published stem cell cost guide, which is what licensed MSC protocols in our network run, escrowed all-in:
| Program | Typical all-in range | What's included |
|---|---|---|
| SCI stem cell program (MSC, licensed Boao pilot or registered trial) | $8,000–18,000 per course — typical China band from our published guide; exact protocol pricing for SCI [TO-VERIFY] | Hospital, physician, cell product, nursing, room, translation, coordination |
| MSC + exosome combo protocols | $12,000–28,000 per course | Hospital, physician, cell product, nursing, room, translation, coordination |
| Eligibility workup (pre-travel) | $800–2,000 | Records review, remote physician consult, screening labs |
| Follow-up program (12 months) | $2,000–5,000 | Remote monitoring, telehealth consults, lab coordination |
Compare: US stem cell clinics routinely charge $50,000–150,000 for unproven, FDA-unsanctioned treatments with zero regulatory oversight (published in our diabetes guide). China's licensed Boao pathway is typically 30–60% less and operates under a real regulatory framework with a real hospital behind it. If your case ultimately points to complex spine surgery rather than a cell program, our hospital guides publish surgical pricing too — complex spine surgery runs $15,000–28,000 all-in at network hospitals like West China Hospital versus $80,000–150,000 in the US.
We only publish price tables for programs we've verified directly. Our own China figures below come from our published stem cell guide; foreign-market figures for SCI specifically are not published on this site, so we've marked them [TO-VERIFY] rather than invent numbers. Verify any figure with the provider before committing.
| Market / program | Typical range (USD) | Regulatory status |
|---|---|---|
| China — Boao Lecheng, VCC network programs | $8,000–18,000 per course (published MSC band); SCI-specific quote [TO-VERIFY] | Licensed pilot-zone protocols, Grade 3A hospitals, escrowed payment |
| China — other broker listings (Boao) | $15,000–35,000 (published broker-listing range) | Same zone — verify hospital and protocol before comparing prices |
| United States | $25,000–60,000 per MSC course (published in our stem cell guide); SCI-specific [TO-VERIFY] | FDA has approved no MSC therapy for spinal cord injury as of 2026 |
| Switzerland / Germany | [TO-VERIFY] — not published on this site | Varies; some clinics operate under compassionate-use rules |
| Mexico (Tijuana / Monterrey) | [TO-VERIFY] — not published on this site | Largely unregulated; no mandatory outcome tracking |
| Thailand | [TO-VERIFY] — not published on this site | Semi-regulated; oversight varies by hospital |
Why the table reads this way: our published guides cover China's licensed programs directly, and we refuse to quote foreign-market prices we haven't verified. The China numbers above are real published bands from our network; anything marked [TO-VERIFY] gets verified — with the provider, in writing — before you commit. Treat any sub-$8,000 quote as a cue to verify the hospital and protocol, not as a deal.
China's Hainan Free Trade Port and the Boao Lecheng International Medical Tourism Pilot Zone are the government-designated venue for advanced licensed therapies, and our network also includes neuro/spine-strong hospitals like West China Hospital (Chengdu), whose international medical center handles over 10,000 foreign visits a year. Key facts we've published:
Our escrow structure is the same one documented across this site — and it matters even more for SCI, where outcomes are slow-moving and hype is loud:
No — as of 2026 no stem cell product for spinal cord injury has NMPA marketing approval anywhere, including China. Treatment happens under licensed trial or pilot-zone frameworks. Anyone claiming an "NMPA-approved SCI stem cell treatment" is misstating the regulatory status.
No licensed program claims full functional restoration. Licensed programs offer a regulated protocol with realistic, measurable goals for eligible patients — typically modest functional gains combined with rehabilitation — under a documented treatment plan. Outcomes vary and are never guaranteed.
Yes, enormously. Most licensed commercial programs require a stable injury, typically 3–12+ months post-injury. Acute-phase protocols exist mainly as registered trials with strict criteria. Your injury timing is the first thing the treating physician will assess.
If you meet inclusion criteria — injury timing, ASIA grade, age and organ-function limits — trial enrollment can reduce or waive treatment cost, but you bear travel and stay costs and must meet strict criteria. We can walk through both paths in your free review.
Describe your case and current treatment. We'll respond within one business day.
💬 Get your estimate on WhatsApp — usually replies within minutes